BlackRock Fund Advisors’s Acceleron Pharma XLRN Stock Holding History

BlackRock Fund Advisors’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$34.4M	Buy	1,347,553 +150,501	+13%	+$4.77M	0.01%	1892
2016 Q3	$43.3M	Buy	1,197,052 +68,974	+6%	+$2.28M	0.01%	1680
2016 Q2	$38.3M	Buy	1,128,078 +57,968	+5%	+$1.88M	0.01%	1672
2016 Q1	$28.2M	Buy	1,070,110 +149,193	+16%	+$4.34M	0.01%	1783
2015 Q4	$44.9M	Sell	920,917 -60,434	-6%	-$2.17M	0.01%	1551
2015 Q3	$24.4M	Buy	981,351 +40,479	+4%	+$1.22M	0.01%	1864
2015 Q2	$29.8M	Buy	940,872 +116,140	+14%	+$3.75M	0.01%	1865
2015 Q1	$31.4M	Buy	824,732 +33,383	+4%	+$1.33M	0.01%	1808
2014 Q4	$30.8M	Buy	791,349 +435,934	+123%	+$15.2M	0.01%	1801
2014 Q3	$10.7M	Sell	355,415 -7,013	-2%	-$198K	﹤0.01%	2304
2014 Q2	$12.3M	Buy	362,428 +162,329	+81%	+$5.43M	﹤0.01%	2294
2014 Q1	$6.9M	Buy	200,099 +25,145	+14%	+$1.13M	﹤0.01%	2620
2013 Q4	$6.93M	Buy	+174,954	New	+$4.22M	﹤0.01%	2596

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BlackRock Fund Advisors's XLRN Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Acceleron Pharma (XLRN) stake by 13% in Q4 2016, buying an estimated $4.77M and bringing the position to 1,347,553 shares worth $34.4M. The position accounts for 0.01% of the portfolio, ranked #1892.

BlackRock Fund Advisors first reported a position in XLRN in Q4 2013 and has held it in 13 quarters since. The position peaked at $44.9M in Q4 2015. 146 funds tracked by Wall St. Rank hold XLRN as of Q4 2016.

BlackRock Fund Advisors held 1,347,553 shares of Acceleron Pharma worth $34.4M as of Q4 2016.
BlackRock Fund Advisors bought 150,501 Acceleron Pharma shares in Q4 2016, an estimated $4.77M.
Acceleron Pharma made up 0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #1892 holding.
BlackRock Fund Advisors first reported a position in Acceleron Pharma in Q4 2013 and has held it in 13 quarters since.
BlackRock Fund Advisors's Acceleron Pharma position peaked at $44.9M in Q4 2015.
146 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.